Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences
31 août 2021 08h30 HE
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results
09 août 2021 08h30 HE
|
Longboard Pharmaceuticals, Inc.
Continued progress with the multiple ascending dose (MAD) portion of the Phase 1 clinical trial for LP352, a potential treatment for severe epileptic indications, with topline results expected in 2021...
Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results
10 mai 2021 16h05 HE
|
Longboard Pharmaceuticals, Inc.
Commenced multiple ascending dose (MAD) portion of the Phase 1 study for LP352, a potential treatment for severe epileptic indications; topline results expected in the second half of 2021 ...
Longboard Pharmaceuticals Announces Pricing of Initial Public Offering
11 mars 2021 21h44 HE
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological...
Longboard Pharmaceuticals Appoints Brandi L. Roberts as Chief Financial Officer
21 janv. 2021 08h30 HE
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological...
Longboard Pharmaceuticals Appoints Phillip Schneider and Paul Sekhri to Board of Directors
20 janv. 2021 16h30 HE
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological...